Concomitant Tricuspid Valve Surgery Is Not Associated With Increased Operative Risk During Robotic Mitral Valve Surgery
Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery · 2024
DOI: 10.1177/15569845231223853 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2024. Verfasst von Gökhan Arslanhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Acibadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Robotic Surgical Procedures, Heart Valve Prosthesis Implantation, Mitral Valve Insufficiency, Tricuspid Valve Insufficiency. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objective
The aim of this study was to investigate the outcomes of robotic mitral valve surgery with and without concomitant tricuspid valve surgery.
Methods
Patients who underwent robotic mitral surgery between March 2010 and September 2022 were included. Patients were grouped according to the presence of concomitant tricuspid interventions. The groups were compared for baseline factors, operative parameters, and early postoperative outcomes. Age- and gender-matched groups were also compared for outcomes.
Results
The study included 285 robotic mitral surgery patients. There were 59 patients who underwent concomitant tricuspid interventions. In the concomitant tricuspid surgery group, cardiopulmonary bypass time (150.1 vs 128.4 min, P < 0.001) and cross-clamp time (99.2 vs 82.4 min, P < 0.001) were longer. Prolonged intubation was more frequent in the concomitant tricuspid intervention group (5.2% vs 0.5%, P = 0.029). The groups did not differ in terms of mortality, permanent pacemaker (PPM) requirement, or other morbidities. Perioperative outcomes were similar after matched group analysis.
Conclusions
Operative mortality and early adverse outcomes did not increase with the addition of tricuspid intervention in our cohort of robotic mitral surgery patients. The robotic approach for mitral disease and coexisting tricuspid disease may offer safe results without an increased risk of postoperative PPM requirement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Acibadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.
- Department of Cardiovascular Surgery, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Research and Training Hospital, Istanbul, Turkey.
- Acibadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.
- Department of Anesthesiology, Acibadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.
- Department of Cardiology, Acibadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.
ORCID-Profile: Zeynep Sıla Özcan
Zitieren
APA
Arslanhan, G., Baştopçu, M., Özcan, Z. S., Şenay, Ş., Koçyiğit, M., Güllü, A. Ü., Akyol, A., & Alhan, C. (2024). Concomitant Tricuspid Valve Surgery Is Not Associated With Increased Operative Risk During Robotic Mitral Valve Surgery. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. https://doi.org/10.1177/15569845231223853
Vancouver
Arslanhan G, Baştopçu M, Özcan ZS, Şenay Ş, Koçyiğit M, Güllü AÜ, et al. Concomitant Tricuspid Valve Surgery Is Not Associated With Increased Operative Risk During Robotic Mitral Valve Surgery. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2024. doi:10.1177/15569845231223853
BibTeX
@article{Arslanhan2024,
author = {Arslanhan, Gökhan and Baştopçu, Murat and Özcan, Zeynep Sıla and Şenay, Şahin and Koçyiğit, Muharrem and Güllü, Ahmet Ümit and Akyol, Ahmet and Alhan, Cem},
title = {Concomitant Tricuspid Valve Surgery Is Not Associated With Increased Operative Risk During Robotic Mitral Valve Surgery},
journal = {Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery},
year = {2024},
doi = {10.1177/15569845231223853}
}
EUVIMED